ConductScience.org, home

Paper32420063

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib.

Buder A and 4 others. Transl Lung Cancer Res, 2020. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. Papers, record 32420063. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32420063

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib.
PubMed
Journal
Transl Lung Cancer Res
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.07
iCite
Revised in PubMed
2022-04-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Buder AAnna
2Hochmair MJMaximilian J
3Setinek UUlrike
4Pirker RRobert
5Filipits MMartin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130922878
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Lancet Respir Med2019https://conductscience.org/library/papers/30922878PubMed
227055085Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.JAMA Oncol2016https://conductscience.org/library/papers/27055085PubMed
326730486The potential of liquid biopsies.Curr Opin Oncol2016https://conductscience.org/library/papers/26730486PubMed
430810887EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.Target Oncol2019https://conductscience.org/library/papers/30810887PubMed
531411950Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.J Clin Oncol2020https://conductscience.org/library/papers/31411950PubMed
624429876Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.Clin Cancer Res2014https://conductscience.org/library/papers/24429876PubMed
727959700Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/27959700PubMed
825829397Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.Clin Cancer Res2015https://conductscience.org/library/papers/25829397PubMed
929151359Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29151359PubMed
1030539501Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.Target Oncol2019https://conductscience.org/library/papers/30539501PubMed
1129505901Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.J Thorac Oncol2018https://conductscience.org/library/papers/29505901PubMed
1230397287The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.Br J Cancer2018https://conductscience.org/library/papers/30397287PubMed

Download CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
41097693Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm.Cancers (Basel)2025https://conductscience.org/library/papers/41097693PubMed
40825939The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomark Med2025https://conductscience.org/library/papers/40825939PubMed
39998904Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.Oncologist2025https://conductscience.org/library/papers/39998904PubMed
38162173
Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure.
JTO Clin Res Rep2023https://conductscience.org/library/papers/38162173PubMed
38012343Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.Sci Rep2023https://conductscience.org/library/papers/38012343PubMed
37390764Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.ESMO Open2023https://conductscience.org/library/papers/37390764PubMed
37240238Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis.Int J Mol Sci2023https://conductscience.org/library/papers/37240238PubMed
36969743Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells.Cancer Res Commun2022https://conductscience.org/library/papers/36969743PubMed
36928816A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.Nat Med2023https://conductscience.org/library/papers/36928816PubMed
36848029Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.Front Med2023https://conductscience.org/library/papers/36848029PubMed
35713632Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).Clin Cancer Res2022https://conductscience.org/library/papers/35713632PubMed
35004240EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.Transl Lung Cancer Res2021https://conductscience.org/library/papers/35004240PubMed
34771566Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.Cancers (Basel)2021https://conductscience.org/library/papers/34771566PubMed
34743498[Application Value of ctDNA-based MRD Dedection in Early Stage Non-small Cell Lung Cancer after Radical Surgery].Zhongguo Fei Ai Za Zhi2021https://conductscience.org/library/papers/34743498PubMed
34527339Genomic alteration profiles of lung cancer and their relationship to clinical features and prognosis value using individualized genetic testing.J Thorac Dis2021https://conductscience.org/library/papers/34527339PubMed
34430591Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.Ann Transl Med2021https://conductscience.org/library/papers/34430591PubMed
34427045EGFR-plasma mutations in prognosis for non-small cell lung cancer treated with EGFR TKIs: A meta-analysis.Cancer Rep (Hoboken)2022https://conductscience.org/library/papers/34427045PubMed
34073111Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR.Cancers (Basel)2021https://conductscience.org/library/papers/34073111PubMed
33919291Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.Biomolecules2021https://conductscience.org/library/papers/33919291PubMed
33842353Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs.Front Oncol2021https://conductscience.org/library/papers/33842353PubMed

See all 22 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32420063

GET https://conductscience.org/api/papers/v1/32420063/cited_by?page=2